- Home
- ZNTL vs FATE Comparison
ZNTL vs FATE Comparison
Compare ZNTL & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- FATE
- Stock Information
- Founded
- ZNTL 2014
- FATE 2007
- Country
- ZNTL United States
- FATE United States
- Employees
- ZNTL N/A
- FATE N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZNTL Health Care
- FATE Health Care
- Exchange
- ZNTL Nasdaq
- FATE Nasdaq
- Market Cap
- ZNTL 105.8M
- FATE 116.5M
- IPO Year
- ZNTL 2020
- FATE 2013
- Fundamental
- Price
- ZNTL $1.67
- FATE $1.45
- Analyst Decision
- ZNTL Buy
- FATE Hold
- Analyst Count
- ZNTL 6
- FATE 6
- Target Price
- ZNTL $6.53
- FATE $3.30
- AVG Volume (30 Days)
- ZNTL 689.2K
- FATE 2.4M
- Earning Date
- ZNTL 11-11-2025
- FATE 11-11-2025
- Dividend Yield
- ZNTL N/A
- FATE N/A
- EPS Growth
- ZNTL N/A
- FATE N/A
- EPS
- ZNTL N/A
- FATE N/A
- Revenue
- ZNTL $26,865,000.00
- FATE $8,470,000.00
- Revenue This Year
- ZNTL N/A
- FATE N/A
- Revenue Next Year
- ZNTL N/A
- FATE N/A
- P/E Ratio
- ZNTL N/A
- FATE N/A
- Revenue Growth
- ZNTL N/A
- FATE N/A
- 52 Week Low
- ZNTL $1.01
- FATE $0.66
- 52 Week High
- ZNTL $4.44
- FATE $3.50
- Technical
- Relative Strength Index (RSI)
- ZNTL 50.91
- FATE 68.11
- Support Level
- ZNTL $1.54
- FATE $0.95
- Resistance Level
- ZNTL $1.69
- FATE $1.46
- Average True Range (ATR)
- ZNTL 0.09
- FATE 0.11
- MACD
- ZNTL 0.00
- FATE 0.04
- Stochastic Oscillator
- ZNTL 54.35
- FATE 83.64
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.